Dermata Therapeutics (DRMA) Free Cash Flow (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Free Cash Flow of -$2.5 million for Q1 2026, down 28.21% year-over-year from -$3.5 million in Q1 2025, and down 77.12% quarter-over-quarter from -$1.4 million in Q4 2025.
Dermata Therapeutics (DRMA) Free Cash Flow (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 28.21% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$8.3 million (up 19.7% YoY), while the FY2025 annual figure was -$7.8 million, up 30.13% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$2.5 million, down from -$1.4 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.1 million in Q4 2023, with the low at -$3.4 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$1.9 million (2025), against an average of -$2.2 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 235.97% in 2022, then jumped 51.95% in 2025.
- Dermata Therapeutics' Free Cash Flow stood at -$1.8 million in 2022, then soared by 37.15% to -$1.1 million in 2023, then tumbled by 153.95% to -$2.9 million in 2024, then surged by 51.95% to -$1.4 million in 2025, then tumbled by 77.12% to -$2.5 million in 2026.
- Business Quant data shows DRMA's Free Cash Flow at -$2.5 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | -2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.48 Mn |
| Mar 31, 2026 | -2.48 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -2.67 Mn |
| Jun 30, 2025 | -2.67 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Dec 31, 2024 | -2.91 Mn |
| Dec 31, 2024 | -2.91 Mn |
| Sep 30, 2024 | -3.42 Mn |
| Sep 30, 2024 | -3.42 Mn |
| Jun 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -2.13 Mn |
| Mar 31, 2024 | -2.70 Mn |
| Mar 31, 2024 | -2.70 Mn |
| Dec 31, 2023 | -1.15 Mn |
| Dec 31, 2023 | -1.15 Mn |